Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Core Insights - Genmab has announced a partnership with Anthropic to enhance its research and development processes through AI capabilities, aiming to bring transformative antibody medicines to patients [1][2] Group 1: Partnership Details - The collaboration will involve designing and deploying custom AI solutions powered by Claude to support Genmab's clinical development priorities [2] - Genmab's teams will utilize Claude for accelerating data processing, analysis, and document generation, which will streamline operational activities and improve consistency in clinical programs [2][4] Group 2: Strategic Goals - This partnership is a significant step in Genmab's transformation towards a more scalable and efficient R&D model aligned with its AI strategy [3] - By reducing manual tasks, the partnership will allow Genmab's teams to focus on high-value scientific and strategic work, ultimately aiming to accelerate the delivery of therapies to patients [3][4] Group 3: Company Background - Genmab is an international biotechnology company focused on improving the lives of cancer patients through innovative antibody medicines, with a strong late-stage clinical pipeline [5][6] - The company has over 25 years of experience in advancing various antibody-based therapeutic formats and has powered eight approved antibody medicines [5]